Playbook
What should I actually do about rheumatoid arthritis?
Rheumatoid arthritis is an autoimmune disease that inflames the joints and, untreated, damages them permanently. It is about three times more common in women. The single most important thing is speed: getting diagnosed early and treated to a target protects your joints.
Rheumatoid Arthritis · reviewed July 2026 · 13 cited papers
See a clinician promptly if
- !Persistent swelling in the small joints of the hands or feet with over an hour of morning stiffness. Suggests inflammatory arthritis, and getting to a rheumatologist quickly, during the "window of opportunity," gives the best chance of preventing joint damage.
- !A single hot, red, exquisitely painful joint. Could be a septic (infected) joint or gout, both of which need urgent, different care.
- !Fever or feeling very unwell while on immune-suppressing RA drugs. These medications raise infection risk, so serious infection needs prompt evaluation.
Step 1
Is it rheumatoid arthritis?
Joint pain has many causes. These are the features that point to inflammatory rheumatoid arthritis rather than wear-and-tear osteoarthritis or something else, and it is worth acting fast because early treatment works best.
Step 2
What to get checked
Diagnosis combines the pattern of joints, blood tests, and sometimes imaging. These are the key tests.
Anti-CCP antibodies and rheumatoid factor
Anti-CCP in particular supports the diagnosis and predicts more aggressive, antibody-positive disease.
Inflammatory markers (CRP and ESR)
Reflect the level of inflammation and help track disease activity over time.
Joint imaging (ultrasound or x-ray)
Can detect inflammation or early erosions and help confirm the diagnosis.
Baseline bloods before starting DMARDs
Liver, kidney, and blood-count checks are needed before and during methotrexate and other drugs.
Step 3
What good treatment looks like
The evidence is clear: treat early, aim for a target, and adjust until you get there. This is roughly the sequence.
Treat-to-target from the start
Set a target of remission or low disease activity, measure disease activity regularly, and escalate treatment until you reach it. This approach dramatically outperforms hands-off care.
TimelineReassessed every few months until at target.
Methotrexate as the anchor drug
The usual first-line disease-modifying drug and the backbone others build on, often started with a short steroid bridge. It takes several weeks to work, and folic acid reduces side effects.
TimelineWeeks to months for full effect.
How to get itPrescription.
CautionsUnsafe in pregnancy and must be stopped well before conceiving. Needs regular blood monitoring and caution with alcohol.
Biologics (such as TNF inhibitors)
If methotrexate is not enough within a few months, adding a biologic like a TNF inhibitor controls disease and protects joints, especially in aggressive early RA.
TimelineWeeks to months.
How to get itPrescription, specialist-managed.
CautionsRaise infection risk; need TB and hepatitis screening before starting.
Exercise and stopping smoking
Regular physical activity is safe and improves function and disease activity without harming joints, and it should be treated as part of care. Stopping smoking lowers risk and improves outcomes.
JAK inhibitors, with caution in higher-risk patients
Effective oral drugs, but a large safety trial found more heart events and cancers than TNF inhibitors in patients over 50 with a cardiovascular risk factor, so they are used more selectively.
How to get itPrescription.
CautionsDiscuss your personal heart, clot, and cancer risk before starting.
Set your expectations
- Early, aggressive treatment is what protects your joints, so pushing for a fast diagnosis matters.
- Methotrexate and biologics take weeks to months, so give a treatment a fair trial before judging it.
- The goal is remission or low disease activity; if you are not there, the plan should change.
- RA raises heart disease risk, so blood pressure, cholesterol, and not smoking are part of RA care.
Step 4
Take this to your doctor
“I have symmetrical joint pain and swelling with long morning stiffness, and I want to be assessed quickly for rheumatoid arthritis so we do not lose the early treatment window.”
Questions to ask
- Do I have inflammatory arthritis, and are my anti-CCP and inflammatory markers checked?
- What target are we treating to, and how often will we reassess?
- Where am I in the treatment sequence, and what is the next step if I am not at target?
- Given my age and risk factors, which drugs are safest for me?
What to bring
- A record of which joints are affected and how long morning stiffness lasts
- Your smoking history and any pregnancy plans (methotrexate must be stopped beforehand)
- Any prior blood tests including CRP, ESR, RF, and anti-CCP
When to push. Ask for an urgent rheumatology referral if you have persistent small-joint swelling, since early treatment prevents damage, and for pre-pregnancy medication review.
Step 5
Where the science is going
Refining who benefits from which drug
Research is working toward biomarkers that predict who will respond to methotrexate or specific biologics, which would reduce trial-and-error. For now, treat-to-target with regular reassessment is the proven approach.
All sources
Every claim above links to peer-reviewed research. Full list below.
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. (2010). Arthritis & Rheumatism. doi.org/10.1002/art.27584
- Rheumatoid arthritis. (2016). Lancet. doi.org/10.1016/S0140-6736(16)30173-8
- Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. (2004). Lancet. doi.org/10.1016/S0140-6736(04)16676-2
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. (2016). Annals of the Rheumatic Diseases. doi.org/10.1136/annrheumdis-2015-207524
- Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. (2016). Nature Reviews Rheumatology. doi.org/10.1038/nrrheum.2016.175
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (2023). Annals of the Rheumatic Diseases. doi.org/10.1136/ard-2022-223356
- The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. (2006). Arthritis & Rheumatism. doi.org/10.1002/art.21519
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. (2022). New England Journal of Medicine. doi.org/10.1056/NEJMoa2109927
- 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. (2018). Annals of the Rheumatic Diseases. doi.org/10.1136/annrheumdis-2018-213585
- Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. (2011). Annals of the Rheumatic Diseases. doi.org/10.1136/ard.2009.120899
- Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. (2008). Arthritis & Rheumatism. doi.org/10.1002/art.24003
- Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. (2012). Annals of the Rheumatic Diseases. doi.org/10.1136/annrheumdis-2011-200726
- An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. (2003). Annals of the Rheumatic Diseases. doi.org/10.1136/ard.62.3.208
This playbook is educational and is not medical advice. Hair loss has many causes and individual treatment decisions belong with a clinician who can examine you.